NEW YORK (GenomeWeb) – Nemucore and the Medical Prognosis Institute (MPI) announced today that they have partnered to identify potential responder patients for enrollment in a clinical trial of an undisclosed Nemucore cancer therapeutic.

Under the deal, Nemucore will use MPI's Drug Response Predictor Biomarker platform — which is used to develop tumor-derived gene signatures that may be predictive of how patients respond to certain oncology treatment — to potentially select participants for a planned Phase IIb study of one of its cancer drug candidates.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.